The new 6th Edition continues to be the definitive pocket-sized guide on the "hows" and "whys" of cardiovascular drugs. It provides in-depth information on all of the drug classes used to treat heart disease, and covers drug use, new drug classes, drug use for single and multiple problem management, and more. A user-friendly organization speed readers to the information they need, and dynamic new full-color drawings illustrate key pharmacological and physiological actions. The new edition includes access to the companion website, which offers bi-annual content updates to keep you current with new drugs, indications and leading trials. The website also has the feature of fully searchable text to access book content via drug, disease or drug action.

Authoritative, portable, and up to date, Opie's Cardiovascular Drugs, 9th Edition, is the definitive reference for quick access to frequently used drugs in all phases of care for cardiac patients. Now a part of the Braunwald family of renowned cardiology references, this compact title provides crucial information in an easily accessible format-ideal for cardiologists, residents, cardiology fellows, medical students, nurses, and other cardiac care providers. Updated to include the latest guidelines and evidence-based implications, it offers clear and concise explanations and pertinent clinical facts for all classes of cardiac drugs, as well as all the latest clinical trial results and evidence for the pharmacologic treatment of heart disease. Uses a new, consistent format for each drug class: overview and guidelines for use, mechanisms of action, differences among drugs in class, data for use, side effects, and drug interactions. Covers key topics such as new ESC and NLA guidelines, advances in lipid-lowering therapy, new diabetes drugs that improve cardiovascular outcomes, obesity drugs and cardiovascular and metabolic effects, drugs targeting inflammation, and combinations of antithrombotic therapies with analysis of risk-benefit. Provides guidance on how to effectively manage comorbid diseases. Contains dozens of unique "Opiegram" diagrams that demystify complex mechanisms of action and other drug processes-many updated to reflect current pathologic understanding of mechanisms. Enhanced eBook version included with purchase, which allows you to access all of the text, figures, and references from the book on a variety of devices

"EACPR, European Association for Cardiovascular Prevention and Rehabilitation -- European Society of Cardiology."

This South Asia edition of the market-leading cardiac drug resource presents drug and disease scenarios apt for this region. It provides in-depth information on every drug class used to treat heart disease, including the popular "Which Drug for Which Disease" chapter - equipping readers to make effective clinical decisions.. Navigate the latest pharmacologic advances through coverage of the newest drugs and drug classes, as well as all the latest clinical trial results and evidence. . Effectively manage comorbid diseases. . Apply international insights-thanks to new global contributors. . Visualize key pharmacologic and physiologic actions-thanks to dynamic new full-color drawings. • Navigate the latest pharmacologic advances through coverage of the newest drugs and drug classes, as well as all the latest clinical trial results and evidence. • Effectively manage comorbid diseases. • Apply international insights—thanks to new global contributors. • Visualize key pharmacologic and physiologic actions—thanks to dynamic new full-color drawings.

The Social Security Administration (SSA) uses a screening tool called the Listing of Impairments to identify claimants who are so severely impaired that they cannot work at all and thus immediately qualify for benefits. In this report, the IOM makes several recommendations for improving SSA's capacity to determine disability benefits more quickly and efficiently using the Listings.

The Heart and Toxins brings together global experts to provide the latest information and clinical trials that make the connection between genetic susceptibility, gene expression, and environmental factors in cardiovascular diseases. This unique reference, edited by renowned cardiologist Meenakshi Sundaram Ramachandran, solves the problem of managing multiple clinical cases of cardiovascular toxicity. It allows connections to be made between research, diagnosis, and treatment to avoid higher morbidity and mortality rates as a result of cardiovascular toxicity. - Structured to bring together exploration into the epidemiology, molecular mechanism, pathogenesis, environmental factors and management in cardiovascular toxins - Included various topics on cardiovascular toxins such as plant, chemical, animal, nanomaterial and marine biology induced cardiac damage – which are new ideas discussed in detail - Comprehensive chapters on the cardiovascular toxicity from drugs, radiotherapy and radiological imaging - Enables you to manage multiple clinical cases of cardiovascular toxicity - Outlined conclusions at the end of each chapter providing "key learning points to help you organize the chapter's details without losing insight

This practical handbook, organised both by clinical condition and specific drug for easy access to information, contains pharmacological data and up-to-date evidence for the clinical uses of each drug in an easily digestible and accessible format.